Lupin Limited — Updates, 13-05-2025: Press Release

Lupin has announced a board meeting on the launch of Tolvaptan Tablets (15 mg to 90 mg) in the U.S., following FDA approval. The company secures 180-day exclusivity for the generic of Jynarque®, a treatment for slowing kidney decline in ADPKD. With the original drug’s U.S. sales at USD 1,467 million annually, this launch presents significant revenue upside for Lupin.